Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line study of nivolumab + relatlimab plus chemotherapy versus pembrolizumab plus chemotherapy in PD-L1-positive nonsquamous advanced or recurrent NSCLC
CTR20244845Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, relatlimab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Dec 2024; status: active.
02
Drugs
nivolumabrelatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244845.